Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 5,922 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mouth Disease Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Oropharyngeal Candidiasis (OPC) and S-ECC

NCT05761197
View directory record Official record
Conditions
Candida Infection, Oral Thrush, Early Childhood Caries
Interventions
Not listed
Lead sponsor
Temple University
Other
Eligibility
9 Months to 15 Months
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 4, 2026, 1:54 AM EST
Completed Phase 4 Interventional Results available

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

NCT00323297
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Bosentan, Placebo, Sildenafil Citrate
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
6
States / cities
Los Angeles, California • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Nov 4, 2026, 1:54 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral Nitrite for Older Heart Failure Patients

NCT02457260
View directory record Official record
Conditions
Heart Failure
Interventions
14 N Sodium Nitrite
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
70 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Nov 4, 2026, 1:54 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting Conditions

NCT00602524
View directory record Official record
Conditions
Dry Mouth
Interventions
Pilocarpine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 4, 2026, 1:54 AM EST
Completed Not applicable Interventional

A Pilot Clinical Trial of Gintuit (TM)in Establishing a Functional Zone of Attached Gingiva

NCT01547962
View directory record Official record
Conditions
Gingival Recession
Interventions
Gintuit, autologous Free Gingival Graft (FGG)
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2012 · Synced Nov 4, 2026, 1:54 AM EST
Completed Phase 1 Interventional

Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy

NCT00222443
View directory record Official record
Conditions
Lymphomas, Tumors
Interventions
Irinotecan
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
1 Year to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 22, 2008 · Synced Nov 4, 2026, 1:54 AM EST
Completed Early Phase 1 Interventional Results available

Melatonin Versus Placebo in Breast Cancer

NCT01805089
View directory record Official record
Conditions
Breast Cancer
Interventions
Melatonin 3 mg
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Nov 4, 2026, 1:54 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions

NCT00618059
View directory record Official record
Conditions
Dry Mouth
Interventions
Pilocarpine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 4, 2026, 1:54 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 4, 2026, 1:54 AM EST
Completed Phase 1 Interventional

A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia

NCT01635296
View directory record Official record
Conditions
Myelogenous Leukemia, Acute
Interventions
RO5045377, cytarabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Valhalla, New York • Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 4, 2026, 1:54 AM EST
Completed Not applicable Interventional

Effect of Sensory Adapted Dental Environment on Dental Anxiety of Children With Intellectual and Developmental Disabilities

NCT03218462
View directory record Official record
Conditions
Developmental Disability, Intellectual Disability, Dental Anxiety
Interventions
Sensory Adapted Dental Environment (SADE)
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Nov 4, 2026, 1:54 AM EST
Completed Phase 1 Interventional

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

NCT00954226
View directory record Official record
Conditions
Recurrent Head and Neck Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Nov 4, 2026, 1:54 AM EST
Completed Phase 3 Interventional

Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT02570490
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
sodium fusidate, linezolid
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
12 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
60
States / cities
Anaheim, California • Bakersfield, California • Buena Park, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Nov 4, 2026, 1:54 AM EST
Recruiting Phase 2 Interventional

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

NCT06997068
View directory record Official record
Conditions
Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8, Head and Neck Cancer, Hypopharynx Cancer, Oropharynx Cancer, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Hypopharyngeal Carcinoma, Metastatic Laryngeal Carcinoma, Metastatic Malignant Head and Neck Neoplasm, Metastatic Oropharyngeal Carcinoma, Recurrent Hypopharyngeal Carcinoma, Recurrent Laryngeal Carcinoma, Recurrent Malignant Head and Neck Neoplasm, Recurrent Oropharyngeal Carcinoma, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Celecoxib, Erlotinib Hydrochloride, Imaging Procedure, Interview, Methotrexate, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 4, 2026, 1:54 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Product Characteristics on the Abuse Liability of Nicotine Pouches

NCT07165808
View directory record Official record
Conditions
Nicotine Addiction
Interventions
Nicotine pouch: Low dose, Nicotine pouch: High dose, Low pH, High pH
Other
Lead sponsor
Emory University
Other
Eligibility
21 Years to 35 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 4, 2026, 1:54 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

NCT01734785
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin, Empagliflozin + Linagliptin, Empagliflozin placebo + Linagliptin placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
28
States / cities
Gulf Shores, Alabama • Norwalk, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 4, 2026, 1:54 AM EST
Recruiting Phase 2 Interventional

A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

NCT07812090
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Oral BGE-102, Oral Placebo Matching BGE-102, Anti-VEGF, Sham
Drug · Other
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Bakersfield, California • Glendale, California • Mountain View, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 4, 2026, 1:54 AM EST
Active, not recruiting Phase 2 Interventional

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04329325
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive
Interventions
Blinatumomab, dasatinib, dexamethasone, methotrexate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 4, 2026, 1:54 AM EST
Recruiting Phase 1 Interventional

A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the Body

NCT07525960
View directory record Official record
Conditions
Diabetes Insipidus
Interventions
NDI-5001
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Santa Ana, California • Jacksonville, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 4, 2026, 1:54 AM EST
Completed Phase 2 Interventional Results available

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

NCT03497806
View directory record Official record
Conditions
Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI, Recurrent C. Diff, rCDI, C. Difficile, Recurrent CDI, FMT, Fecal Microbiota, Fecal Transplant
Interventions
CP101
Biological
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
53
States / cities
Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Nov 4, 2026, 1:54 AM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety of Oral BT-11 in Ulcerative Colitis

NCT03861143
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BT-11 (440 mg), BT-11 (880 mg), Placebo
Drug
Lead sponsor
NImmune Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Los Angeles, California • Ventura, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Nov 4, 2026, 1:54 AM EST
Completed Phase 1 Interventional

Study of Radiolabeled Revumenib in Adults With Acute Leukemia

NCT05406817
View directory record Official record
Conditions
Acute Leukemia
Interventions
Revumenib
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Nov 4, 2026, 1:54 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Serum Hepcidin Immunoassay - Laboratory to Marketplace

NCT03310736
View directory record Official record
Conditions
Anemia, Iron Deficiency
Interventions
Intrinsic Hepcidin IDx™ Test
Diagnostic Test
Lead sponsor
Intrinsic LifeSciences, LLC
Industry
Eligibility
11 Years and older
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Nov 4, 2026, 1:54 AM EST
Terminated Phase 2 Interventional Results available

Preventing Alcohol Withdrawal With Oral Baclofen

NCT01937364
View directory record Official record
Conditions
Alcoholism, Alcohol Withdrawal
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Essentia Health
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Duluth, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Nov 4, 2026, 1:54 AM EST